Background illustration for clinical trials search

Paid Clinical Trials Oklahoma City

Discover 570 paid clinical trials in Oklahoma City, Oklahoma. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter

Filter results

Results: 570

Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation

for

Prostate Adenocarcinoma, Stage IIIB Prostate Cancer AJCC v8,

Location: Oklahoma City OK, Kearney NE, Lincoln NE, Papillion NE,

Sponsor: SWOG Cancer Research Network

Sex: Male

Age: 18+

Code: NCT05806515

Phase2, Recruiting

A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

for

Ovarian Carcinoma

Location: Oklahoma City OK, Springfield MO, Overland Park KS,

Sponsor: NRG Oncology

Sex: Female

Age: 35 - 50

Code: NCT04251052

Recruiting

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

for

Carcinoma, Non-Small Cell Lung,

Location: Oklahoma City OK, Irving TX, Springdale AR,

Sponsor: Seagen, a wholly owned subsidiary of Pfizer

Sex: All

Age: 18+

Code: NCT04389632

Phase1, Recruiting

Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

for

Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma,

Location: Oklahoma City OK, Springdale AR, Fayetteville AR,

Sponsor: SWOG Cancer Research Network

Sex: All

Age: 18+

Code: NCT05633615

Phase2, Recruiting

Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial

for

Advanced Esophageal Adenocarcinoma,

Location: Oklahoma City OK, Lawton OK, Salina KS, Hays KS,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT06203600

Phase2, Phase3, Recruiting

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

for

Acute Myeloid Leukemia

Location: Oklahoma City OK, Topeka KS, Overland Park KS,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT06317649

Phase2, Recruiting

A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT

for

Anaplastic Kidney Wilms Tumor, Recurrent Kidney Wilms Tumor,

Location: Oklahoma City OK, Dallas TX, Fort Worth TX, Lubbock TX,

Sponsor: Children's Oncology Group

Sex: All

Age: 0 - 30

Code: NCT04322318

Phase2, Recruiting

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

for

Classic Follicular Lymphoma,

Location: Oklahoma City OK, Springdale AR, Fayetteville AR,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT06337318

Phase3, Recruiting

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

for

Acute Myeloid Leukemia,

Location: Oklahoma City OK, Salina KS, Hays KS, Topeka KS,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT05564390

Phase2, Recruiting

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

for

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

Location: Oklahoma City OK, Salina KS, Hays KS, Topeka KS,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT04269902

Phase3, Recruiting

A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss

for

Childhood Medulloblastoma

Location: Oklahoma City OK, Dallas TX, Kansas City MO,

Sponsor: Children's Oncology Group

Sex: All

Age: 4 - 21

Code: NCT05382338

Phase3, Recruiting

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

for

Recurrent Lung Non-Small Cell Carcinoma,

Location: Oklahoma City OK, Lawton OK, Salina KS, Amarillo TX,

Sponsor: SWOG Cancer Research Network

Sex: All

Age: 18+

Code: NCT06616584

Phase2, Phase3, Recruiting

A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases

for

Acral Lentiginous Melanoma,

Location: Oklahoma City OK, Fort Smith AR, Joplin MO,

Sponsor: SWOG Cancer Research Network

Sex: All

Age: 18+

Code: NCT04511013

Phase2, Recruiting

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

for

Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8,

Location: Oklahoma City OK, Springfield MO, Topeka KS,

Sponsor: NRG Oncology

Sex: Male

Age: 18+

Code: NCT05946213

Phase3, Recruiting

Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

for

Metastatic Nasopharyngeal Carcinoma,

Location: Oklahoma City OK, Omaha NE, Council Bluffs IA,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT06029270

Phase2, Recruiting

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

for

Advanced Lung Non-Small Cell Carcinoma,

Location: Oklahoma City OK, Fort Smith AR, Joplin MO,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT03191149

Phase2, Recruiting

Milrinone for Prevention of Post-ligation Cardiac Syndrome Trial

for

Post-ligation Cardiac Syndrome

Location: Oklahoma City OK, Dallas TX, Houston TX, Memphis TN,

Sponsor: NICHD Neonatal Research Network

Sex: All

Age: 0

Code: NCT06679855

Phase3, Recruiting

Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

for

Intracranial Meningioma, Recurrent Meningioma,

Location: Oklahoma City OK, Fort Smith AR, Joplin MO,

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All

Age: 18+

Code: NCT02523014

Phase2, Recruiting

Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body

for

Castration-Resistant Prostate Carcinoma,

Location: Oklahoma City OK, Springdale AR, Fayetteville AR,

Sponsor: SWOG Cancer Research Network

Sex: Male

Age: 18+

Code: NCT06470243

Phase3, Recruiting

Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial

for

Metastatic Renal Cell Carcinoma,

Location: Oklahoma City OK, Tulsa OK, Richardson TX, Dallas TX,

Sponsor: NRG Oncology

Sex: All

Age: 18+

Code: NCT05327686

Phase2, Recruiting

Paid Clinical Trials Oklahoma City

Filter results

Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation

A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial

Interested in new trials?

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

Milrinone for Prevention of Post-ligation Cardiac Syndrome Trial

Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body

Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial